Atomic structure of a rationally engineered gene delivery vector, AAV2.5

被引:20
|
作者
Burg, Matthew [1 ]
Rosebrough, Claire [1 ]
Drouin, Lauren M. [1 ,6 ]
Bennett, Antonette [1 ]
Mietzsch, Mario [1 ]
Chipman, Paul [1 ]
McKenna, Robert [1 ]
Sousa, Duncan [2 ]
Potter, Mark [3 ,4 ]
Byrne, Barry [3 ,4 ]
Samulski, R. Jude [5 ]
Agbandje-McKenna, Mavis [1 ]
机构
[1] Univ Florida, Coll Med, Dept Biochem & Mol Biol, McKnight Brain Inst, Gainesville, FL 32610 USA
[2] Florida State Univ, Dept Biol Sci, Biol Sci Imaging Resource, 89 Chieftan Way,Rm 119, Tallahassee, FL 32306 USA
[3] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA
[4] Univ Florida, Coll Med, Powell Gene Therapy Ctr, Gainesville, FL 32610 USA
[5] Univ N Carolina, Dept Pharmacol, Gene Therapy Ctr, Chapel Hill, NC 27515 USA
[6] Voyager Therapeut Inc, Cambridge, MA USA
关键词
Adeno-associated virus; cryo-EM; Vector engineering; Structure-guided design; Parvovirus; THERAPY; TRANSDUCTION; INSIGHTS; BINDING; CELLS; MODEL;
D O I
10.1016/j.jsb.2018.05.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
AAV2.5 represents the first structure-guided in-silica designed Adeno-associated virus (AAV) gene delivery vector. This engineered vector combined the receptor attachment properties of AAV serotype 2 (AAV2) with the muscle tropic properties of AAV1, and exhibited an antibody escape phenotype because of a modified antigenic epitope. To confirm the design, the structure of the vector was determined to a resolution of 2.78 angstrom using cryo-electron microscopy and image reconstruction. The structure of the major viral protein (VP), VP3, was ordered from residue 219 to 736, as reported for other AAV structures, and the five AAV2.5 residues exchanged from AAV2 to AAV1, Q263A, T265 (insertion), N706A, V709A, and T717N, were readily interpretable. Significantly, the surface loops containing these residues adopt the AAV1 conformation indicating the importance of amino acid residues in dictating VP structure.
引用
收藏
页码:236 / 241
页数:6
相关论文
共 50 条
  • [31] Gene therapy following subretinal AAV5 vector delivery is not affected by a previous intravitreal AAV5 vector administration in the partner eye
    Li, Wensheng
    Kong, Fansheng
    Li, Xia
    Dai, Xufeng
    Liu, Xiaoqiang
    Zheng, Qinxiang
    Wu, Ronghan
    Zhou, Xiangtian
    Lue, Fan
    Chang, Bo
    Li, Qiuhong
    Hauswirth, William W.
    Qu, Jia
    Pang, Ji-jing
    MOLECULAR VISION, 2009, 15 (26-29): : 267 - 275
  • [32] Retargeting gene delivery using surface-engineered retroviral vector particles
    Lavillette, D
    Russell, SJ
    Cosset, FL
    CURRENT OPINION IN BIOTECHNOLOGY, 2001, 12 (05) : 461 - 466
  • [33] Preclinical Evaluation of an Aav Gene Therapy Vector Engineered to Advance Efficacious Factor IX Expression with Decreased Vector Capsid Exposure
    Sun, Junjiang
    Gui, Tong
    Wichlan, David
    Booth, Carmen J.
    Hannah, William B.
    McPhee, Scott W.
    Samulski, R. Jude
    Monahan, Paul E.
    AMERICAN JOURNAL OF HEMATOLOGY, 2012, 87 : S162 - S163
  • [34] AAV-Containing Exosomes as a Novel Vector to Improve AAV-Mediated Myocardial Gene Delivery in Resistance to Neutralizing Antibody
    Liang, Yaxuan
    Mathiyalagan, Prabhu
    Kohlbrenner, Erik
    Chepurko, Elena
    Jeong, Dongtak
    Ceholski, Delaine
    Dubois, Nicole
    Hajjar, Roger
    Sahoo, Susmita
    CIRCULATION, 2017, 136
  • [35] A Vector Independent Method of Neutralizing Antibody Evasion Potently Protects AAV for Efficient Gene Delivery
    Askew, Charles
    Li, Chengwen
    MOLECULAR THERAPY, 2020, 28 (04) : 22 - 22
  • [36] Recombinant AAV Vector-Mediated Gene Delivery for the Potential Treatment of Adenosine Deaminase Deficiency
    Silver, Jared
    Jayandharan, Giridhara R.
    Cruz, Pedro
    Zhong, Li
    Elder, Melissa
    Srivastava, Arun
    Flotte, Terence R.
    MOLECULAR THERAPY, 2009, 17 : S117 - S117
  • [37] AAV4 AS A DELIVERY VECTOR FOR CFTR GENE TRANSFER TO CF PIG SMALL AIRWAYS
    Li, X.
    Brommel, C.
    Mather, S. E.
    Ehler, A.
    Chen, O.
    Karp, P.
    Girgis, R.
    Stoltz, D. A.
    Zabner, J.
    PEDIATRIC PULMONOLOGY, 2020, 55 : S239 - S239
  • [38] AAV-Containing Exosomes as a Novel Vector for Improved Gene Delivery to Lung Cancer Cells
    Liu, Bin
    Li, Zhiqing
    Huang, Shi
    Yan, Biying
    He, Shan
    Chen, Fengyuan
    Liang, Yaxuan
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [39] CNS-restricted Transduction and CRISPR/Cas9-mediated Gene Deletion with an Engineered AAV Vector
    Murlidharan, Giridhar
    Sakamoto, Kensuke
    Rao, Lavanya
    Corriher, Travis
    Wang, Dan
    Gao, Guangping
    Sullivan, Patrick
    Asokan, Aravind
    MOLECULAR THERAPY-NUCLEIC ACIDS, 2016, 5 : e338
  • [40] Gene therapy of Canavan disease:: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain
    Janson, C
    McPhee, S
    Bilaniuk, L
    Haselgrove, J
    Testaiuti, M
    Freese, A
    Wang, DJ
    Shera, D
    Hurh, P
    Rupin, J
    Saslow, E
    Goldfarb, O
    Goldberg, M
    Larijani, G
    Sharrar, W
    Liouterman, L
    Camp, A
    Kolodny, E
    Samulski, J
    Leone, P
    HUMAN GENE THERAPY, 2002, 13 (11) : 1391 - 1412